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149) degrees of change.  Results: Covariance analysis con-
trolling for the effect of age and education revealed that the 
ADAS-cog differentiated only the mild and severe WMH 
groups, while the differences between all three groups were 
highly significant with the VADAS-cog.  Conclusions:  The 
VADAS-cog significantly differentiated between all the white 
matter groups. In comparison, the ADAS-cog differentiated 
only severe changes. Accordingly, the VADAS-cog may be a 
more sensitive endpoint in studies of patients with white 
matter load and vascular burden of the brain. 
 Copyright © 2007 S. Karger AG, Basel 
 Introduction 
 Progressive impairment of memory and other cogni-
tive functions in age-related diseases has made it impor-
tant to develop concise and easily applied global cognitive 
measurement tools. The Alzheimer’s Disease Assessment 
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 Abstract 
 Background/Aims: The Alzheimer’s Disease Assessment 
Scale cognitive subscale (ADAS-cog) is a widely used rating 
instrument. The Vascular Dementia Assessment Scale cogni-
tive subscale (VADAS-cog) includes additional tests reflect-
ing mental speed and executive functions. The objective of 
this study was to compare the results of the two scales 
among subjects with various degrees of white matter hyper-
intensities (WMHs).  Methods:  In the multicentre, multina-
tional Leukoaraiosis and Disability in the Elderly (LADIS) 
study, 616 non-disabled subjects between the ages of 65 
and 84 were examined using MRI, the ADAS-cog and VADAS-
cog. The WMH rating from the MRI divided the patients into 
groups of mild (n = 280), moderate (n = 187) and severe (n = 
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Scale (ADAS) was designed by Rosen et al.  [1] in order to 
produce a rating instrument for detecting cognitive 
change in Alzheimer’s disease (AD). The cognitive sub-
test (ADAS-cog) has proven to be sensitive to AD pro-
gression, especially at the moderate stage  [1–4] . Based on 
the sensitivity, the ADAS-cog has been adopted for eval-
uation of treatment efficacy in randomised clinical trials 
(RCTs) and proven to be a significant outcome measure 
in trials with AD  [5–7] as well as with Parkinson’s disease 
 [8] . A number of RCTs have shown favourable cognitive 
effects as measured with the ADAS-cog in vascular de-
mentia (VAD)  [9–12] and AD with cerebrovascular dis-
ease  [13–16] . Widening the scope of research to mild AD 
and mild cognitive impairment (MCI), a need has arisen 
to develop additional tasks. Tasks such as delayed recall 
of a word list, maze and digit cancellation have been 
found to be impaired in mild AD  [17] , and the modified 
ADAS-cog has shown favourable treatment effects in 
MCI  [18] .
 The ADAS-cog has marked advantages, based on its 
substantial data confirming reliability and validity and 
its use in measuring longitudinal change together with 
sensitivity to treatment effects. However, the data are 
mainly based on AD research. So far, little is known of its 
sensitivity in other conditions, like vascular cognitive 
impairment (VCI)  [19] , subcortical ischaemic vascular 
disease  [20] or white matter hyperintensities (WMHs). In 
a series of patients with lacunar infarcts, white matter 
changes did not independently influence performance in 
the ADAS-cog  [21] . However, in a larger series of subjects 
with WMHs, an association was found  [22] . The ADAS-
cog was developed to assess AD patients and may not suf-
ficiently capture the specific cognitive deficits of other 
diseases. Both VCI and white matter changes have been 
specifically related to executive functions, attention and 
mental speed  [23–26] . A revision of the ADAS-cog, called 
Vascular Dementia Assessment Scale cognitive subscale 
(VADAS-cog), has been proposed in order to provide a 
better measure in vascular conditions  [27, 28] . In addi-
tion to the original ADAS-cog developed by Rosen et al. 
 [1] , recommended additional tests include a delayed re-
call of a word list task, digit cancellation task, maze task, 
symbol digit test, digit span backward test and verbal flu-
ency test (animal category)  [28] .
 There is a growing need for more sensitive cognitive 
screening tools for elderly individuals in a variety of clin-
ical entities. In addition, development of more sensitive 
outcome measures for clinical studies and RCTs is impor-
tant. Studies of the sensitivity of the VADAS-cog are still 
few. The objective of the present study is to compare the 
results of the ADAS-cog and the VADAS-cog among sub-
jects with various degrees of WMHs in the Leukoaraiosis 
and Disability in the Elderly (LADIS) study.
 Materials and Methods 
 The LADIS study is a multicentre and multinational prospec-
tive follow-up study of initially non-disabled elderly patients with 
different degrees of age-related white matter changes (see detailed 
description in Pantoni et al.  [29] ). Baseline data were collected in 
11 European centres. Subjects were entered into the study if neu-
roimaging revealed the presence of WMHs of any degree. Other 
inclusion criteria were an age of between 65 and 84; no or mild 
disability as assessed by the Instrumental Activities of Daily Liv-
ing (IADL) scale  [30] (none or only one domain affected); the 
presence of an informant, and agreement to sign an informed 
consent. Exclusion criteria were the presence of severe illness (e.g. 
cardiac disease, cancer, hepatic disease) or severe unrelated neu-
rological diseases; leucoencephalopathies of non-vascular origin 
revealed by brain imaging; the presence of severe psychiatric dis-
orders; the inability to give informed consent, or the inability or 
refusal to undergo cerebral MRI. The total number of subjects 
recruited was 639. Complete data from all needed tests were avail-
able for 616 subjects. Stratification of subjects was prespecified 
based on the degree of WMHs  [29] .
 Clinical data were gathered using clinical and functional 
tests, including global functioning, motor, psychiatric, and ac-
tivities of daily living measures. Background and clinical data in 
this study consisted of age, sex, education, history of stroke and 
major depression and activities of daily living measured by the 
IADL scale  [30] . Cognitive assessment included global measures 
like Mini Mental State Examination (MMSE)  [31] , and ADAS-
cog  [1] and VADAS-cog extensions  [28] (see detailed description 
in Madureira et al.  [32] ). The ADAS-cog was designed according 
to Rosen et al.  [1] , except for the modification that the word lists 
were presented only once. The scoring system is the same as in 
the original version. The maximum score in 8 subtests is 5, while 
the 2 word list tasks are scored according to words not recalled 
(maximum 10 and 12), and in orientation the maximum number 
of mistakes is 8. The range of scores is from 0 to 70, a higher score 
indicating lower performance. The VADAS-cog includes 6 ad-
ditional subtests: the delayed recall of a word list task (10 words), 
the digit cancellation test (the number of correct digits cancelled 
in 45 s), the maze task (the time to complete the task and the 
number of errors), the symbol digit test (the number of correct 
responses in 90 s), the digit span backward test (the number of 
digits recalled backwards) and the verbal fluency test (animal 
category in 1 min)  [28] . The delayed recall of a word list is scored 
like other ADAS-cog items (number of words not recalled). In the 
5 other additional tests, the range of raw scores is far too wide to 
be summarized for the total score, and these scores have to be 
transformed in order to be able to make a summary score for the 
VADAS-cog comparable to the ADAS-cog. Percentile scores can 
be applied and used in various settings  [33] , and are similar to 
the ADAS-cog subtest scores. The percentiles of raw scores for 
maze (time score) and digit span backward were analysed in 5 
categories (every 20th percentile) and scored so that 1 represents 
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the best performance and 5 the worst. The symbol digit test, the 
digit cancellation test and the verbal fluency test were similarly 
changed to percentiles, but in 10 categories (every 10th percen-
tile) due to the large range of raw scores; 1 represents the best 
performance and 10 the worst (see Appendix 2 for the conver-
sion). A subgroup of 195 subjects from the LADIS study group 
was used for transforming the VADAS-cog additional tests. The 
inclusion criteria for the standardization group were no global 
cognitive impairment (MMSE score = more than 26), indepen-
dent in daily living (all IADL functions = 1, i.e., no impairment) 
and no history of stroke or major depression. The mean age of 
this subgroup was 74 years (SD = 5.3), the mean duration of edu-
cation was 10.3 years (SD = 3.4) and 143 (73%) of the subjects were 
females.
 MRI was studied according to the standard protocol. Scans 
were made on 0.5-tesla or 1.5-tesla scanners and the series in-
cluded axial T 2 -weighted images [echo time (TE) 100–120 ms; 
repetition time (TR) 4,000–6,000 ms; voxel size 1  ! 1  ! 5–7.5 
mm 3 ; 19–24 slices]; axial fluid-attenuated inversion recovery im-
ages (TE 100–140 ms; TR 6,000–10,000 ms; inversion time 2,000–
2,400 ms; voxel size 1  ! 1  ! 5–7.5 mm 3 ; 19–24 slices), and a 
coronal or sagittal 3-dimensional T 1  sequence (TE 4–7 ms; TR 
10–25 ms; flip angle 15–30°; voxel size 1  ! 1  ! 1–1.5 mm 3 ). MRI 
data were collected centrally at the Image Analysis Centre of the 
Vrije Universiteit Medical Centre, Amsterdam, the Netherlands. 
All ratings were performed by an experienced rater (E.v.S.) blind-
ed to the clinical data. The degree of WMH severity was rated on 
the fluid-attenuated inversion recovery images using the visual 
scale of Fazekas et al.  [34] : mild = 1 (punctuate), moderate = 2 
(early confluent), severe = 3 (confluent). For a more detailed MRI 
protocol, see Pantoni et al.  [29] , van Straaten et al.  [35] , and van 
der Flier et al.  [22] .
 The demographic characteristics and MMSE results of the 
three WMH groups were evaluated with analysis of variance and 
a    2  test. The continuous items of the ADAS-cog were examined 
with analysis of variance, while the categorical items of the ADAS-
cog were analysed by the    2  test. The categorical variables were 
heavily weighted to a zero score, and a cut-off point of 2 was used 
for the categories 2–5. The additional tests included in the VADAS-
cog were individually evaluated between the three WMH groups 
by univariate analysis of variance. The Pearson correlation was 
calculated between the possible confounding demographic fac-
tors and the ADAS-cog and the VADAS-cog tests. Furthermore, 
univariate analysis of covariance controlling for the effect of age 
and education was performed between the three WMH groups 
and the ADAS-cog and the VADAS-cog results. Finally, a step-
wise discriminant analysis was performed for the additional 
VADAS-cog tests, in order to identify those subtests that contrib-
ute most to the differences between the WMH groups.
 Results 
 The characteristics of the study sample in the three 
different white matter groups are presented in  table 1 . 
The white matter degree grew significantly with age, and 
there was also some variation with sex.
 The results for ADAS-cog items are presented in  ta-
ble 2 . Five out of 11 items showed significant results be-
tween the white matter groups. The categorical variables 
of construction, naming, apraxia, word finding and com-
prehension showed statistically significant differences 
between the three white matter groups.
 Analysis of variance showed significant differences 
between the WMH groups in delayed recall, verbal flu-
ency, symbol digit, digit cancellation and maze ( table 3 ). 
We used the time score of the maze task, because the er-
ror score showed a floor effect [552 (90%) of subjects with 
0; 53 (8%) with 1, and 11 (2%) with 2 errors].
 The association between the ADAS-cog and the 
VADAS-cog total scores and age and education was eval-
uated using Pearson correlation and between these tests 
and sex using analysis of variance (for a more detailed 
evaluation of background variables and cognitive tests, 
see Madureira et al.  [32] ). Age correlated significantly 
with the ADAS-cog (r = 0.16, p  ! 0.01) and the VADAS-
cog (r = 0.24, p  ! 0.01). Education correlated significant-
ly with both the ADAS-cog (r = –0.25, p  ! 0.01) and the 
VADAS-cog (r = –0.42, p  ! 0.01). In a univariate analysis 
of variance, sex did not show a relationship with either 
cognitive scale (ADAS-cog: F = 3.0, p = 0.08; VADAS-cog: 
F = 0.66, p = 0.41). With analysis of covariance, we evalu-
ated the association between white matter changes and 
cognitive tests by controlling for the effects of age and 
education. The covariate-adjusted estimates of group 
means and pairwise comparisons are presented in  fig-
ures 1 and  2 . After controlling for age and education, the 
significance of the ADAS-cog diminished (F = 3.9; p = 
0.02), and in pairwise analysis it was shown that only 
WMH group 1 and WMH group 3 significantly differed 
from each other. In the VADAS-cog, however, the differ-
ences remained highly significant even after controlling 
for age and education (F = 16.2; p = 0.000), and statistical 
significance was revealed between all three degrees of 
WMHs ( fig. 2 ). We repeated the analysis of covariance 
with the subgroup of subjects (n = 420; WMH group 1:
n = 163, WMH group 2: n = 132, WMH group 3: n = 125) 
who were not enrolled in the test transformation group 
(Appendix 2). The ADAS-cog did not show a significant 
relationship with the white matter changes after control-
ling for the effects of age and education (F = 0.96, p = 
0.38). The VADAS-cog test differed significantly between 
the WMH groups in the analysis of covariance (F = 5.58, 
p = 0.004). A direct comparison of these tests would re-
quire a different setting and design. A rough estimate of 
how well these tests classify the subjects in the WMH 
groups was performed by discriminant function analysis. 
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The ADAS-cog correctly classified 45.8% of subjects, 
while the VADAS-cog correctly classified 47.9% of sub-
jects.
 A stepwise discriminant analysis was performed to 
identify the combination of the VADAS-cog additional 
tests that best discriminate between the degrees of WMHs. 
The stepwise method selected digit cancellation (F to en-
ter = 26.9; Wilks   = 0.92; exact F = 26.9, p = 0.000), fol-
lowed by verbal fluency (F to enter = 4.2; Wilks   = 0.91; 
exact F = 15.3, p = 0.000). No other variable entered in the 
analysis. The symbol digit test also had a high F to enter 
(22.6) at step 0, but as it highly correlated with the digit 
cancellation test (r = 0.75), it was not entered into the 
analysis. 
 Discussion 
 Examining the relationship between the ADAS-cog, 
the VADAS-cog and white matter changes in a large 
group of community-dwelling subjects with white matter 
changes, we found that 5 out of 11 tasks of the ADAS-cog 
showed an association with the degree of WMHs. The 
summary score of the ADAS-cog was different in the 
mild versus severe WMH groups after controlling for the 
effects of age and education, but not in the mild versus 
moderate or moderate versus severe WMH groups. In 
contrast, in the VADAS-cog, 5 out of 6 additional tests 
showed a significant relationship with WMH severity. 
The total score of the VADAS-cog differed highly signif-
icantly in all three white matter groups, even after con-
trolling for age and education. The VADAS-cog proved 
to be a more sensitive measure to reflect the white matter 
load than the ADAS-cog. Discriminant analysis showed 
that the digit cancellation and verbal fluency tests were 
the most useful additional subtests in the VADAS-cog in 
showing differences between the WMH groups. Tests 
that measure processing speed and executive functions 
showed relative importance in association with white 
matter changes in this study group.
 This is the first study applying the modification of the 
ADAS-cog proposed by Ferris  [27, 28] , and no stan-
dardised summary score system has been developed. The 
delayed recall of a word list is scored like other ADAS-cog 
items (number of words not recalled). The 5 other addi-
tional tests differ in the scoring system, and the raw scores 
cannot be summarised for the total score. The range of 
the additional test scores is wider and more variable com-
pared to the other ADAS-cog items and the frequency 
distribution corresponds to a normal curve. We did not 
want to use any arbitrary cut-off points; instead we used 
the percentile scores when transforming the raw scores 
 [33] . In this way, the individual tests could be summarised 
similarly to the ADAS-cog system.
 In a few previous studies, the additional tasks of the 
ADAS-cog have been analysed separately  [17, 36] . In 
some, the additional task of delayed recall of a word list 
has been added to the ADAS-cog score  [18] . The digit 
cancellation test proved to be a useful additional task in 
measuring mild Alzheimer patients  [17] , while in a series 
of MCI subjects the additional tests of symbol digit, digit 
cancellation and verbal fluency did not show significant 
results  [36] . Various studies have proven that the relation-
ship between white matter changes and cognition is spe-
cific, concentrating on executive functions, attention and 
mental speed  [22, 25] . Executive deficits have also been 
found to be one of the most prominent features in sub-
cortical ischaemic vascular disease  [20, 24] . VCI has been 
related to deficits in attention, executive functions, and 
slowing of performance  [19] . Executive and psychomotor 
Table 1. Characteristics of the LADIS study group (n = 616) and differences among the three WMH groups 
(mild: WMH group 1; moderate: WMH group 2; severe: WMH group 3)
Total
(n = 616)
WMH group 1
(n = 280)
WMH group 2
(n = 187)
WMH group 3
(n = 149)
F
Age (mean 8 SD), years 73.985.1 73.285.0 74.385.2 75.084.8 6.5**
Female 340 (55.2%) 157 (56.1%) 113 (60.4%) 70 (47%) 6.2* (2)
Education (mean 8 SD), years 9.683.8 9.883.7 9.783.9 9.383.9 1.1
MMSE score (mean 8 SD) 27.482.4 27.782.0 27.582.3 26.782.9 9.1***
F = Univariate analysis of variance.
Statistical analysis between the three WMH groups: * p < 0.05; ** p < 0.01; *** p < 0.001. 
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difficulties have been found to be similar in VCI and 
VAD, only differing in the degree of severity  [37] . The 
ADAS-cog has shown to be a significant cognitive out-
come measure in previous RCTs on VAD  [9–12] and AD 
with cerebrovascular disease  [13–16] . However, more 
sensitive cognitive screening tools and more sensitive 
outcome measures are needed in order to detect even 
mild or specific cognitive changes and beneficial treat-
ment effects. The VADAS-cog aims to measure cognitive 
domains affected in vascular conditions. We found that 
the VADAS-cog had a highly significant association with 
the three degrees of WMHs, while the ADAS-cog showed 
Total
(n = 616)
WMH
group 1
(n = 280)
WMH
group 2
(n = 287)
WMH
group 3
(n = 149)
ADAS-cog
Word recall 5.181.6 5.081.7 4.981.5 5.381.7 1.9
Word recognition 2.882.4 2.782.2 2.982.5 2.982.5 0.8
Orientation 0.381.0 0.280.8 0.481.3 0.480.9 1.7
Subtests
Following command
0 437 (71) 196 (70) 139 (74) 102 (68)
1 153 (25) 77 (27) 40 (21) 36 (24)
2–5 26 (4.2) 7 (2.5) 8 (4.3) 11 (7.4) 7.6 
Construction
0 319 (52) 165 (59) 86 (46) 68 (45)
1 264 (43) 107 (38) 82 (44) 75 (50)
2–5 23 (5) 8 (3) 19 (10) 6 (4) 20.3**
Naming
0 517 (84) 245 (87) 156 (83) 116 (78)
1 90 (15) 33 (12) 30 (16) 27 (18)
2–5 9 (1.5) 2 (1) 1 (0.5) 6 (4) 13.0*
Ideational apraxia
0 532 (86) 255 (91) 154 (82) 123 (83)
1 62 (10) 19 (7) 23 (12) 20 (13)
2–5 22 (3.6) 6 (2.2) 10 (5.4) 6 (4) 10.2*
Remembering instructions
0 532 (86) 246 (88) 164 (88) 122 (82)
1 54 (9) 25 (9) 14 (7.5) 15 (10)
2–5 30 (5) 9 (3.3) 9 (5) 12 (8) 5.8
Spoken language
0 563 (91) 262 (94) 173 (92) 128 (86)
1 41 (7) 13 (5) 11 (6) 17 (11)
2–5 12 (2) 5 (2) 3 (1.6) 4 (2.7) 8.1
Word finding
0 509 (83) 242 (86) 159 (85) 108 (72)
1 86 (14) 32 (11) 24 (13) 30 (20)
2–5 21 (3.4) 6 (2) 4 (2) 11 (7.3) 17.1**
Comprehension
0 489 (79) 239 (85) 145 (77) 105 (70)
1 80 (13) 28 (10) 22 (12) 30 (20)
2–5 47 (7.6) 12 (4.6) 20 (11) 14 (9.4) 17.0**
ADAS-cog total 10.485.2 9.684.3 10.685.7 11.585.9 6.3**
Statistical analysis between the three WMH groups: F values (univariate analysis of 
variance) for ADAS-cog and ADAS-cog total and 2 for the subtests. * p < 0.05; ** p < 
0.01. Figures in parentheses are percentages. 
Table 2. Results of the LADIS study 
group (n = 616) in the ADAS-cog test
and subtests and the differences among 
the three WMH groups  (mild: WMH 
group 1; moderate: WMH group 2; 
 severe: WMH group 3)
 Ylikoski  et al.
 
Dement Geriatr Cogn Disord 2007;24:73–8178
significant results only between the mild versus severe 
WMHs. The additional tasks measure executive func-
tions, flexibility, attention and psychomotor speed, and 
these tests significantly improved the sensitivity of the 
ADAS-cog in measuring the subjects’ white matter 
changes. The term ‘executive functions’ has been applied 
to a set of higher-order cognitive processes that control, 
integrate, organize and maintain cognitive abilities. Var-
ious methods have been used in assessing different as-
pects of executive functions. Verbal fluency reflects 
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 Fig. 1. Analysis of covariance between white matter changes – 
mild WMHs (group 1), moderate WMHs (group 2), severe WMHs 
(group 3) – and the ADAS-cog summary score. Covariates are age 
and education. The corrected means (standard errors) are: WMH 
group 1 = 9.8 (0.3); WMH group 2 = 10.5 (0.4); WMH group 3 = 
11.2 (0.4); F = 3.9, p = 0.02. The mean difference between WMH 
group 1 and WMH group 2 is –0.7 (p = 0.12), between WMH 
group 2 and WMH group 3 –0.68 (p = 0.22) and between WMH 
group 1 and WMH group 3 –1.4 (p = 0.01). 
 Fig. 2. Analysis of covariance between white matter changes – 
mild WMHs (group 1), moderate WMHs (group 2), severe WMHs 
(group 3) – and the VADAS-cog summary score. Covariates are 
age and education. The corrected means (standard errors) are: 
WMH group 1 = 38.7 (0.6); WMH group 2 = 41.9 (0.8); WMH 
group 3 = 44.9 (0.9); F = 16.2, p = 0.000. The mean difference 
 between WMH group 1 and WMH group 2 is –3.1 (p = 0.002), 
between WMH group 2 and WMH group 3 –3.1 (p = 0.01) and 
between WMH group 1 and WMH group 3 –6.2 (p = 0.000). 
Total
(n = 616)
WMH
group 1
(n = 280)
WMH
group 2
(n = 187)
WMH
group 3
(n = 149)
F
Delayed recall 5.882.4 5.582.4 6.182.3 6.182.4 5.5*
Digit span 5.4681.7 5.581.7 5.681.7 5.181.7 4.0
Verbal fluency 19.186.2 20.186.0 19.486.0 16.986.2 13.7**
Symbol digit 26.9810.9 29.7810.7 26.1810.4 22.680.7 22.6**
Digit cancellation 19.686.7 21.587.0 19.086.2 16.985.7 26.9**
Maze 7.385.9 6.784.6 7.185.6 8.688.0 4.9*
VADAS-cog 41.2812.6 38.1811.8 42.0812.5 45.9812.4 20.7**
F = Univariate analysis of variance between the three WMH groups.
* p < 0.05; ** p < 0.001.
Table 3. Results of  the LADIS study 
group (n = 616) in the VADAS-cog test 
and subtests and the differences among 
the three WMH groups (mild: WMH 
group 1; moderate: WMH group 2; 
 severe: WMH group 3)
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memory retrieval strategies and mental flexibility  [38, 
39] . The digit span backward test has been used as a mea-
sure of working memory  [40] . The maze test, which usu-
ally includes various increasingly complex tasks, is af-
fected among other things by planning abilities  [40] . The 
digit cancellation and the symbol digit tests are thought 
to reflect attention and speed of performance as well as 
flexibility  [41] . Further development of the VADAS-cog 
might be indicated according to our results. The digit 
span backward test did not differ between the three study 
groups. The maze task was problematic, because the error 
score showed heavy floor effects (most subjects with no 
errors). The time score was not very sensitive in this study 
sample. Our results revealed that the best discrimination 
could be achieved by the digit cancellation and verbal flu-
ency tests. This is a preliminary study presenting results 
of the VADAS-cog test. More research is needed with dif-
ferent diagnostic groups and sensitivity/specificity esti-
mations in order to find the best combination. Our re-
sults indicate that both attention/speed, measured by 
digit cancellation, and executive functions/flexibility, 
measured by verbal fluency, are important domains 
when studying white matter changes, while the digit 
span backward test and the maze task were not so useful 
in this study design.
 Our results are limited to independent, community-liv-
ing subjects with white matter diseases. More research 
with subcortical ischaemic vascular disease, VCI and VAD 
subjects is required to verify the usefulness of the VADAS-
cog, and if needed to modify the test composition. Al-
though the additional tests of the VADAS-cog have not 
been related to MCI  [36] , their usefulness in detecting cog-
nitive changes and treatment effects in mild AD  [17] could 
be important. The VADAS-cog is based on the ADAS-cog, 
building upon the substantial data confirming its validity 
and longitudinal sensitivity. A limitation of our study de-
sign was that it included only one learning trial of the word 
list task in ADAS-cog. This may affect the scores in this 
item and should be taken into account when evaluating the 
results. The additional tests in the VADAS-cog are also 
widely used and known neuropsychological tests. Exten-
sive research work exists of the ADAS-cog and of the indi-
vidual additional tests in the VADAS-cog. So far, little re-
search has been done of the total score of the VADAS-cog. 
Our results need to be validated in future studies, and 
knowledge of its sensitivity to change in longitudinal stud-
ies is also needed. The strengths of this study include a 
well-characterised population, a large sample size and 
MRI ratings performed by a single centre.
 Most clinical trials have adopted cognitive screening 
assessments that were originally developed to assess 
treatment effects in AD. Executive dysfunction, slowing 
of performance or attention have a minimal impact on 
these scales. Detecting cognitive changes and treatment 
effects, even if they are limited to certain cognitive do-
mains, would increase the sensitivity of the cognitive 
screening tests both in clinical settings and RCTs. Our 
results showed that the VADAS-cog, and especially the 
additional tests measuring processing speed and execu-
tive functions, had a highly significant relationship with 
white matter load.
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 Appendix 1: List of Participants in the LADIS Study 
 Helsinki, Finland (Memory Research Unit, Department of 
Neurology, Helsinki University): Timo Erkinjuntti, MD, PhD; 
Tarja Pohjasvaara, MD, PhD; Pia Pihanen, MD; Raija Ylikoski, 
PhD; Hanna Jokinen, Lic. Psych.; Meija-Marjut Somerkoski, M. 
Psych.; Riitta Mäntylä, MD, PhD; Oili Salonen, MD, PhD.  Graz, 
Austria (Department of Neurology and MRI Institute, Medical 
University): Franz Fazekas, MD; Reinhold Schmidt, MD; Stefan 
Ropele, PhD; Alexandra Seewann, MD; Katja Petrovic, MagPsy-
chol; Ulrike Garmehi.  Lisbon, Portugal (Serviço de Neurologia, 
Centro de Estudos Egas Moniz, Hospital de Santa Maria): José 
M. Ferro, MD, PhD; Ana Verdelho, MD; Sofia Madureira, PsyD. 
 Amsterdam, The Netherlands (Department of Neurology, VU 
Medical Centre): Philip Scheltens, MD, PhD; Ilse van Straaten, 
MD; Alida Gouw, MD; Wiesje van der Flier, PhD; Frederik 
Barkhof, MD, PhD.  Gothenburg, Sweden (Institute of Clinical 
Neuroscience, Goteborg University): Anders Wallin, MD, PhD; 
Michael Jonsson, MD; Karin Lind, MD; Arto Nordlund, PsyD; 
Sindre Rolstad, PsyD; Kerstin Gustavsson, RN.  Huddinge, Swe-
den (Neurotec Department, Section of Clinical Geriatrics, Kar-
olinska Universitetssjukhuset): Lars-Olof Wahlund, MD, PhD; 
Militta Crisby, MD, PhD; Anna Pettersson, physiotherapist; 
Kaarina Amberla, PsyD.  Paris, France (Department of Neurol-
ogy, Hôpital Lariboisière): Hugues Chabriat, MD, PhD; Ludovic 
Benoit, MD; Karen Hernandez, Solene Pointeau, Annie Kurtz, 
Daniel Reizine, MD.  Mannheim, Germany (Department of Neu-
rology, University of Heidelberg, Klinikum Mannheim): Mi-
chael Hennerici, MD; Christian Blahak, MD; Hansjorg Baezner, 
MD; Martin Wiarda, PsyD; Susanne Seip, RN.  Copenhagen, 
Denmark (Copenhagen University Hospital, Memory Disorders 
Research Unit, Department of Neurology, Rigshospitalet, and 
the Danish Magnetic Resonance Research Centre, Hvidovre 
Hospital): Gunhild Waldemar, MD, DMSc; Egill Rostrup, MD, 
 Ylikoski  et al.
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MSc; Charlotte Ryberg, MSc; Tim Dyrby, MSc; Olaf B. Paulson, 
MD, DMSc.  Newcastle-upon-Tyne, UK (Institute for Ageing and 
Health, University of Newcastle): John O’Brien, DM; Sanjeet 
Pakrasi, MRCPsych; Thais Minnet, PhD; Michael Firbank, PhD; 
Jenny Dean, PhD; Pascale Harrison, BSc; Philip English, DCR. 
The coordinating centre is in  Florence, Italy (Department of 
Neurological and Psychiatric Sciences, University of Florence): 
Domenico Inzitari, MD (Study Coordinator); Leonardo Panto-
ni, MD, PhD; Anna Maria Basile, MD; Giovanna Carlucci, MD, 
PhD; Michela Simoni, MD; Giovanni Pracucci, MD; Monica 
Martini, MD; Eliana Magnani, MD; Anna Poggesi, MD; Lucia-
no Bartolini, PhD; Emilia Salvadori, PhD; Marco Moretti, MD; 
Mario Mascalchi, MD, PhD. The LADIS Steering Committee is 
formed by Domenico Inzitari, MD, Timo Erkinjuntti, MD, PhD, 
Philip Scheltens, MD, PhD, Marieke Visser, MD, PhD, and Peter 
Langhorne, PhD.
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